-- Reputation House has released its digital risk report for the pharmaceutical sector, a sector-wide analysis of digital reputation across 17 leading companies with a significant U.S. market presence. Each company was assessed using Risk Check, Reputation House's free AI-powered diagnostic platform, which maps how controllable a company's digital presence is across media and social channels, search results, AI-generated interpretations, and consumer trust signals.
The report finds that digital reputational risk in pharma is structural rather than episodic. It is shaped less by current crises than by accumulated legal history, fragmented brand identity, and the growing influence of AI-generated content on how a brand is perceived.
Across the 17 companies, the average Composite Risk Score is 33 out of 100, where a higher score indicates greater exposure. That places the sector average just above the boundary between the LOW and MEDIUM bands. Eleven companies landed in MEDIUM and six in LOW, with a high of 42 and a low of 24.
"For years, pharmaceutical companies have invested in managing search results and press coverage, and those investments still matter. But a new discovery surface has emerged. When a patient, an investor, or a journalist asks an AI system about a company today, the answer often leans on decades of indexed regulatory and litigation history rather than on where the company stands now. That gap between how a company presents itself and how AI describes it is the reputational challenge of this decade, and it's one that traditional communications was never built to address. We built Risk Check so companies can finally see that problem and act on it," said Kristina Shinkareva, CEO of Reputation House.
The most striking result concerns AI. Every company scored MEDIUM on AI Perception – the dimension that measures the gap between how a company positions itself and how AI systems like ChatGPT, Gemini, and Perplexity describe it. At this sample size, the metric doesn't yet differentiate between companies, so the report treats this as an early-stage, observational signal rather than a settled finding. But the pattern is clear enough to act on. AI systems draw heavily on the most authoritative and most heavily indexed sources – encyclopedias, news archives, government and litigation records — and for pharmaceutical brands that material disproportionately reflects regulatory actions, warning letters, pricing lawsuits, and historical controversies. Even companies with otherwise strong digital profiles inherit this framing. The legal matter may be long resolved; the digital signal persists.
This is the central takeaway of the report. As AI becomes a primary discovery surface for patients, investors, and journalists, companies face a new category of risk that traditional PR and search-optimization frameworks were never built to measure: the gap between institutional reputation and AI-mediated perception. Alongside it, the report identifies brand-identity fragmentation – from spinoffs, name collisions, and subsidiary confusion – as a persistent, cross-channel vulnerability that AI systems tend to amplify rather than resolve.
The full report is available at the official website of Reputation House.
About Reputation House
Reputation House is an international technology company specializing in digital risk protection. Our product combines a proprietary platform, an expert team, and an independent research division into a single solution for monitoring and controlling digital reputation risks before they become business losses.
Official website: https://reputation.house
About Risk Check
RiskCheck is a free diagnostic platform that allows companies to assess their level of digital risk in just a few minutes and understand how stable their information environment really is.
Available at: https://checkmyrisks.com
Full Report direct link: https://rc.reputation.house/pharma-reputation-risk-research-2026
Contact Info:
Name: Media Relations
Email: Send Email
Organization: Reputation House
Website: https://reputation.house
Release ID: 89198698
Google
RSS